EU Novel Food Regulation: A Guide for US Exporters

For US wellness, supplement, and ingredient companies, the EU market remains one of the most valuable export destinations — and one of the most regulatorily distinctive. The Novel Food framework under Regulation (EU) 2015/2283 governs which botanical and ingredient products can be placed on the EU market, and the process for novel ingredients is materially slower and more documentation-heavy than the US equivalent.

What "Novel Food" actually means

Under Regulation (EU) 2015/2283, a food is considered "novel" if it was not used for human consumption to a significant degree within the EU before 15 May 1997. That definition catches a much wider range of products than US founders typically expect — including botanicals with a long history of safe use in Asia, Latin America, or Africa but limited pre-1997 EU consumption history [1].

If a botanical intended to be used in food (including food supplements) does not have a documented history of safe use in the EU before 1997, an authorisation under the Novel Food regulation is required before placement on the EU market [2].

The authorisation process, end-to-end

The authorisation process under Regulation (EU) 2015/2283 follows a defined sequence [1][3]:

1. Application is submitted to the European Commission.
2. Administrative and technical validation is performed by EFSA (the European Food Safety Authority).
3. EFSA performs the scientific evaluation — typically 12 to 18 months for a complete dossier.
4. The Commission issues an implementing regulation authorising (or refusing) the novel food and adds it to the EU Union List of authorised novel foods.

In practice, the full cycle from submission to authorisation commonly runs between one and three and a half years, depending on the quality and completeness of the dossier and the number of clock-stops EFSA initiates to request additional information [1].

What goes into the dossier

The technical dossier must include detailed information across multiple domains [2][3]:

• A detailed description of the novel food, including botanical identification, production process, and compositional data.
• Specifications and stability data demonstrating the product is consistent and shelf-stable.
• Proposed uses, use levels, and anticipated intake estimates based on realistic consumption patterns.
• Toxicological data appropriate to the product, including absorption, distribution, metabolism, and excretion (ADME) where applicable.
• Allergenicity assessment.
• History of use evidence, if relevant for traditional foods from third countries (which can route via the simplified procedure under Article 14).

Botanicals get special treatment

EFSA applies particular rigor to botanical safety assessments. Plant products show meaningful diversity in species, varieties, ecotypes, and chemotypes, and cultivation practices influence chemical composition — so the dossier must address how the specific material used in the application maps to the broader plant variability [4].

Commission Regulation (EU) 2022/2340 provides specific guidance on safety evaluation of plant extracts. EFSA also maintains the Compendium of Botanicals as a starting reference for known constituents and concerns [4].

The traditional foods shortcut (Article 14)

For traditional foods from third countries with documented safe use of at least 25 years in a significant population outside the EU, a simplified notification procedure is available. This route is faster and less data-intensive, but documentation of the 25-year safe-use history must be robust — anecdotal evidence does not satisfy the requirement.

Practical guidance for US exporters

• Assess Novel Food status before you commit to the EU market — discovery that your ingredient is novel three months before launch is an 18-month problem.
• Budget realistically: dossier preparation typically costs €100K–€500K plus EFSA's own scientific evaluation timeline.
• Engage a regulatory consultant with EFSA dossier experience early — DIY dossiers are routinely subject to clock-stops that double or triple the timeline.
• Check the EU Union List of authorised novel foods first — your ingredient may already be authorised by another party, in which case you may be able to use that authorisation under specific conditions.
• Plan your stability data programme on EU expectations (typically ≥24 months, varying conditions per ICH guidance).

EU market access is real and valuable, but it requires treating the regulatory work as a product-development line item, not a paperwork afterthought.